242 protocols found



Protocol No. Title Status
A011104 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer Open
A011106 ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study Open
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Open
A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
A021502 A021502: Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*) Open (affiliates only)
A031701 A Phase II study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations Open (affiliates only)
A061202 A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy Open
A081105 Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) (ALCHEMIST) Open
A091302 Ranodmized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer Open (affiliates only)
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Open
A211102 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women Open
A211601 A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502 Open (affiliates only)
A221505 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones Open
AAML1331 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid Open
AAML1531 Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Open
ACCL10P1 Study of Computerized Cognitive Training for Children with Brain Tumors Open
ACCL1633 The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) Open
ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years Open
ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Open
ACNS1721 A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAF Open
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
AGCT1532 Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours Open
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) Open
AHOD1331 A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed High Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents Open
ALTE03N1 Key Adverse Events after Childhood Cancer Open
ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
ALTE1631 A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia Open
ANBL00B1 Neuroblastoma Biology Studies Open
ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma Open
ANBL1531 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) Open
APEC14B1 Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study Open
APEC1621A NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621C NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tazemetostat in Patients with tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Not Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
APEC1621SC NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Open
AREN03B2 Renal Tumors Classification, Biology, and Banking Study Open
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Open
BMTCTN1506 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy following Allogeneic Transplant for Patients with FLT3/ITD AML Open
CALGB30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide Open (affiliates only)
CO11374 A phase II study of pulse reduced Dose rate radiation therapy with Bevacizumab Open
E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults Open
E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST) Open
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy VS Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoaduvant Chemotherapy Open
EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) Open
EA4151 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Cell Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Open
EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Open
EA6134 DREAMSeq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) Trial Open
EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Not Open
EA8143 A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Open
EA8153 Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial Open
EAI142 [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
GOG0278 Evaluation of Physical Function and Quality of Life (QoL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 ( Open (affiliates only)
GOG0279 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Open
GOG3018 The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer (IND 1340) Open
HO07403 A Longitudinal Study to Evaluate Changes in Cellular Protein Expression and Activation in Bone Marrow Tumor Cells and Stromal Cells from Patients with Multiple Myeloma Open
HO11414 Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab + Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Open
LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer Open (affiliates only)
MA39 Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast cancer Open
NCI10104 A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer Open
NCI10129 A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open
NCI9924 A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) Open
NCI9947 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma Open
NCI9950 A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) Open
NHLBI-MDS The National Myelodysplatic Syndromes (MDS) Study Open
NRGBN003 Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma Open
NRGBR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or w/o Carboplatin for Node+ or High-Risk Node- Triple-Neg Invasive Breast Cancer Open (affiliates only)
NRGCC003 A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (SCLC) Open
NRGGI002 A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Open
NRGGU002 Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation following Radical Prostatectomy with or without Adjuvant Docetaxel Open (affiliates only)
NRGGY005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) Open
NRGGY006 A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Open
NRGGY007 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
NRGGY009 A Randomized Phase II/III Study of Pegylated Liposomal Doxorubicin (PLD) and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs. Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Open
NRGHN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic acid (DNA) Open
NRGHN004 Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin Open
NRGLU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer Open (affiliates only)
NSABPB55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo Versus Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Open (affiliates only)
OS11366 FAS Apoptotic Pathway Abnormalities in Cutaneous T-Cell Lymphomas Open (affiliates only)
OS12204 Electrode perturbation based elasticity imaging for ablation monitoring Open
OS12601 T Cell Mutants as BioMarkers in Human Melanoma Open
PO10312 An open label, expanded access protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Open
PRE0403 Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patient with High Tumor Burden Follicular Lymphoma Open
PRE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Open
RO12210 A phase Ia-Ib dose-escalation study evaluating safety and efficacy of neoadjuvant stereotactic body radiotherapy (SBRT) with concomitant capecitabine-based chemotherapy (ChT) for resectable pancreatic adenocarcinoma Open
RTOG0538 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide Open
RTOG0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial Open
RTOG1008 A randomized phase II/phase III study of adjuvant concurrent radiation and chemotherpay versus radiation alone in resected high-risk malignant salivary gland tumors Open
RTOG1119 Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer-A Collaborative Study of NRG Oncology and KrogPha Open
RTOG1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) Open (affiliates only)
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Open
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 cm residual Invasive Cancer or Positive Lymph Node Open
S1500 A Randomized Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [#749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) Open (affiliates only)
S1501 S1501: Prospective Evaluation in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III Open (affiliates only)
S1605 Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer Open
S1608 Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Open
S1612 A Randomized Phase II/III Trial of "Novel Therapeutics: Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older Open (affiliates only)
S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification Open (affiliates only)
S1703 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patient with Metastatic Hormone Receptor Positive Breast Cancer Open (affiliates only)
S1900A A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) Open (affiliates only)
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open
UW13060 Pilot study of short-term bisphosphonate administration as chemopreventive for breast cancer via engagement of gamma-delta T cells Open
UW13061 Pilot Study: Comparison of rpFNA and CNB for Breast Tissue Collection for Chemopreventive Studies Open
UW13089 A Randomized Controlled Trial Evaluating the Impact of Pre-Operative Web-based Breast Cancer Information on the Quality of Patient Decision-Making Open
UW13090 TCR-a/b+ and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors Open
UW13115 Central Neck Dissection in Patients with Clinical Node Negative Thyroid Cancer Open
UW14002 A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 Open
UW14030 Epidural Analgesia as Part of an Enhanced Recovery Pathway in Gynecologic Surgery Open
UW14035 Correlation of tumorigenic properties in early stage breast cancer: an investigation of tumor types, mitotic phenotypes, and tumor microenvironment interactions Open
UW14056 Role of NGS-based ThyroSeq panel in Cancer Diagnosis in Thyroid Nodules Open
UW14070 Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma Open
UW14082 4D Flow MRI of the hepatic vasculature before and after portal vein embolization to predict hypertrophy of the non-embolized hepatic segments Open
UW14083 A Phase I/II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Normal Structure-Sparing IMRT Planning Open
UW14108 Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (CCTL019A2205B) Open
UW15014 Pilot trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients with Castration-Resistant, Metastatic Prostate Cancer Open
UW15017 Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to < 18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours Open
UW15020 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma Open
UW15035 A Prospective review of Radiotherapy delivered with real-time MRI guidance in the treatment of patients with abdominal and pelvic malignancies Open
UW15048 Monitoring microwave ablation of breast tumors via real-time microwave imaging Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW15063 Pembrolizumab in combination with stereotactic body radiotherapy for liver metastatic colorectal cancer Open
UW15103 Real-Time MRI-Guided Stereotactic Body Radiation Therapy and Microwave Ablation for Non-Operable Renal Cell Carcinoma Open
UW15106 Genomic Analysis of Long-Term Survivors with Metastatic Cancer Open
UW15114 A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers with Nuclear Epidermal Growth Factor Receptor Open
UW16009 Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 Open
UW16029 Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice Open (affiliates only)
UW16032 Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma Open
UW16034 Safety of TAS-102 in Combination with Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors Open
UW16037 Improving Pulmonary Function Following Radiation Therapy Open
UW16050 A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Open
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
UW16061 A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL), and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL Open
UW16062 PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Open
UW16063 Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect Open
UW16064 PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning Open
UW16083 A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer Open
UW16086 Bendamustine + obinutuzumab induction chemoimmunotherapy with risk-adapted obinutuzumab maintenance therapy in previously untreated mantle cell lymphoma Open
UW16088 A randoMized phAse II trIal of fulvestraNt or exemestane wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial) Open
UW16102 A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations Open
UW16106 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response Open
UW16110 Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus met XR in Subjects with Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment Open
UW16113 A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW16123 The "Head Start 4" Protocol Newly Diagnosed Children (Less than 10 Years Old) with Medulloblastoma and Other Central Nervous System Embyonal Tumors Open
UW16124 Pediatric myelodysplastic syndrome and bone marrow failure disorder patient registry and tissue repository Open
UW16128 A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients-the INSIGHT-MM study Open
UW16131 A Parallel Phase 2 Study of Glesatinib, Sitravatinib or mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer Open
UW16132 LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Open
UW16137 An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas Open
UW16139 A Pilot Study to Evaluate the Therapeutic Response of Tumor Cells Co-cultured with Non-tumor Cells from Patients with Multiple Myeloma ex vivo Open
UW16140 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Open
UW16144 An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies Open
UW16151 Pharmacodynamic biomarkers of standard anti-microtubule drugs as assessed by early tumor biopsy Open
UW17003 Comprehensive stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer (NSCLC) combined with durvalumab and tremelimumab dual immune checkpoint inhibition Open
UW17009 Pilot neoadjuvant trial of chemohormonal therapy followed by prostatectomy in patients with high risk and oligometastatic prostate cancer Open
UW17010 Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Open
UW17017 PSMA Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging in Gynecological Cancers Open
UW17025 Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease. Open
UW17030 A Pilot Study of Nintedanib in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Open
UW17034 [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer Open
UW17038 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) Open
UW17039 A Randomized, Multicenter, Two-ARM, Single-Dose, Double-Blind, Placebo-Controlled Phase 3 Study of Intravesical Qapzola (Apaziquone) as a Chemotherapy Adjuvant to TransUrethral Resection of Bladder Tumors in Patients with Low-to Intermedicate-Risk Non-Muscle Invasive Bladder Cancer (CONQUER) Open
UW17046 A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PDL1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029 Open
UW17053 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
UW17054 Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology Open
UW17055 A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors Open
UW17064 A Phase II, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Open
UW17073 Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) Open
UW17074 An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castrate-Resistant Prostate Cancer Open
UW17077 Patient Attitudes Toward the Use of Vibrating Vaginal Dilators in Women Who Have Received Radiation for Gynecologic Malignancies Open
UW17078 PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients Open
UW17082 A Phase II, Open-Label, Non-Controlled, Intra-Patient Dose-Escalation Study to Characterize the Pharmacokinetics after Oral Administration of Eltrombopag in Pediatric Patients with Refractory, Relapsed, or Treatment Naïve Severe Aplastic Anemia or Recurrent Aplastic Anemia Open
UW17086 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ubilituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma Open
UW17089 A Postmarketing Prospective Cohort Study of Melanoma Patients Treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients Open
UW17092 Intraoperative use of the OTIS (Optical Tissue Imaging System) in Surgically Excised Lumpectomy Breast Tissue Open
UW17094 Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed with Cancer Open
UW17096 Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach Open
UW17098 Phase 1 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy Open
UW17101 UWCCC Rectal and Anal Cancer Registry Open
UW17103 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS 50%) (KEYNOTE-598) Open
UW17104 Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies Open
UW17106 Phase I/II Trial of Avelumab in Combination with Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer Open
UW17107 Phase 2 Study of ONC201 with and without Methionine-Restricted Diet in Patients with Metastatic Triple Negative Breast Cancer Open
UW17113 A Study of Nivolumab in Combination With Trametinib With or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers Open
UW17114 A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW17121 Prevalence of Abuse in the Sexual Health Clinic Open
UW17125 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial (AFT-25) Open
UW17135  A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors Open
UW17136 A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma Open
UW17141 A Comparison of the Paravertebral Block Versus Pectoralis Block in Controlling Bilateral Post-Mastectomy Pain in Setting of Tissue Expander Open
UW17147 Pre-Visit Planning in Palliative Care Open
UW17149 LUNAR: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure Open
UW17152 An Open-Label Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification Open
UW17154 Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Open
UW17156 Analysis of the Gut Microbiome in Patients Undergoing Autologous PBSCT and Lenalidomide Maintenance for Multiple Myeloma Open
UW17157 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma Open
UW18000 Characterization of the Virome and Microbiome of Normal and Neoplastic Skin of Organ Transplant Recipients Open
UW18007 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Without a Recent History of Blood Transfusion Open
UW18008 Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients with Non-Metastatic, PSA-Recurrent Prostate Cancer Open
UW18009 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax® -AXL-ADC) in patients with solid tumors Open
UW18012 Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Big Ten Cancer Research Consortium: BTCRC-LUN16-081 Open
UW18013 Feasibility and Acceptability of a Telehealth-Based Resistance Training Intervention for Endometrial Cancer Survivors Open
UW18014 A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Open
UW18015 A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma Open
UW18020 Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer Open
UW18025 Monoclonal Antibody-Based Sequential Therapy for Deep remission in Multiple Myeloma - MASTER TRIAL Open
UW18028 A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic treatment Open
UW18036 Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations Open
UW18043 A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy Open
UW18046 Muscle Quality: A Future Target for Nutritional Intervention Open
UW18053 PRO-ACTIVE: Comparing the Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer Open
UW18059 A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Open
UW18062 Communication Between Surgeons and Patients with Thyroid Cancer Open
UW18069 A Randomized Phase 3 Study to Evaluate the Efficcy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGMI Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW18075 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast Cancer Open
UW18083 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study (KEYNOTE 716) Open
UW18087 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients with Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease has not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA) Open
UW18091 The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-H) Open
UW18097 Pilot Inquiry Into the Utility of Lymphocyte Biomarkers in Guiding Immune Checkpoint Inhibitor Therapy In Non-Small Cell Lung Cancer Open
UW18098 A Window of Opportunity Trial of Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) Open
UW18115 Phase I Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Open
UW18120 My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetnib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response with One of these Agents Open
UW18125 A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3 Open
UW18133 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) Open
UW18138 Pilot Study of a Web-based Symptom Cluster Assessment System Open
UW19004 Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors Open
XP09309 Free Oral, Head and Neck Cancer Screening at UWHC Open